American Journal of Cardiology
Volume 96, Issue 11 , Pages 1469-1475 , 1 December 2005

Does Diabetes Mellitus Abolish the Beneficial Effect of Primary Coronary Angioplasty on Long-term Risk of Reinfarction After Acute ST-Segment Elevation Myocardial Infarction Compared With Fibrinolysis? (A DANAMI-2 Substudy)

  • Mette M. Madsen, MD

      Affiliations

    • Department of Cardiology at Skejby Sygehus, Aarhus University Hospital, Aarhus, Denmark.
    • Corresponding Author InformationCorresponding author: Tel: 45-89-496-234; fax: 45-89-496-009.
    • ,
  • Martin Busk, MD

      Affiliations

    • Department of Cardiology at Skejby Sygehus, Aarhus University Hospital, Aarhus, Denmark.
    • ,
  • Hanne M. Søndergaard, MD

      Affiliations

    • Department of Cardiology at Skejby Sygehus, Aarhus University Hospital, Aarhus, Denmark.
    • ,
  • Morten Bøttcher, MD

      Affiliations

    • Department of Cardiology at Skejby Sygehus, Aarhus University Hospital, Aarhus, Denmark.
    • ,
  • Leif S. Mortensen, MSc

      Affiliations

    • UNI-C, Danish Information Technology Center for Education and Research, Aarhus, Denmark.
    • ,
  • Henning R. Andersen, MD

      Affiliations

    • Department of Cardiology at Skejby Sygehus, Aarhus University Hospital, Aarhus, Denmark.
    • ,
  • Torsten T. Nielsen, MD

      Affiliations

    • Department of Cardiology at Skejby Sygehus, Aarhus University Hospital, Aarhus, Denmark.
    • ,
  • DANAMI-2 Investigators

Received 6 May 2005 ,Revised 7 July 2005 ,Accepted 7 July 2005.

  • Image Result

    Cumulative combined event rate (A) and cumulative reinfarction rate (B) for the 4 groups (diabetic patients treated with angioplasty, diabetic patients treated with fibrinolysis, nondiabetic patients

    Cumulative combined event rate (A) and cumulative reinfarction rate (B) for the 4 groups (diabetic patients treated with angioplasty, diabetic patients treated with fibrinolysis, nondiabetic patients treated with fibrinolysis, and nondiabetic patients treated with angioplasty). The p values apply for comparison across 4 groups.

 The DANAMI-2 trial was supported by grants from the Danish Heart Foundation, the Danish Medical Research Council, AstraZeneca, Bristol-Myers Squibb, Cordis, Pfizer, Pharmacia-Upjohn, Boehringer Ingelheim, and Guerbet, Denmark.

PII: S0002-9149(05)01430-X

doi: 10.1016/j.amjcard.2005.07.053

American Journal of Cardiology
Volume 96, Issue 11 , Pages 1469-1475 , 1 December 2005

Article Tools

* Image Usage & Resolution